Enlivex Therapeutics Ltd., a Nasdaq-listed clinical-stage immunotherapy company, has announced compelling six-month efficacy results from the Phase IIa portion of its multinational Phase I\/II Allocetra\u2122 trial for moderate to severe knee osteoarthritis (OA). The latest findings reinforce earlier three-month data and highlight a clear responder population among adults aged 60 and older, suggesting a meaningful therapeutic breakthrough in a field long dominated by pain management rather than disease-modifying solutions.<\/p>\n\n\n\n
The study demonstrated that Allocetra\u2122\u2014a macrophage reprogramming treatment designed to modulate inflammation\u2014produced substantial and durable reductions in pain while improving physical function. In patients aged 60+, the therapy showed a statistically significant improvement at three months, with a 99% greater reduction in composite pain and function scores compared to placebo. At six months, this benefit persisted, with an 80% improvement over placebo in patients aged 61 and older. These results underscore not only efficacy, but durability\u2014an especially notable outcome given that a single treatment cycle generated at least half a year of sustained clinical benefit.<\/p>\n\n\n\n
Equally important, Allocetra\u2122 maintained a favorable safety profile throughout the six-month follow-up, mirroring earlier findings and reinforcing its potential as a viable long-term therapy. As knee osteoarthritis continues to rise due to aging and obesity, experts view innovative immune-modulating strategies as essential. Professor Philip Conaghan, an international leader in OA research, praised the study\u2019s promise, emphasizing the growing need for effective treatments that target inflammatory pathways.<\/p>\n\n\n\n
Enlivex leadership echoed this optimism. CEO Dr. Oren Hershkovitz highlighted both the therapeutic impact and commercial potential, while CMO Dr. Einat Galamidi confirmed plans to launch a Phase IIb trial in early 2026. If future results continue this trajectory, Allocetra\u2122 could represent a transformative new option for millions suffering from age-related knee osteoarthritis.<\/p>\n\n\n\n